Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Prof Carmelo Carlo-Stella speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He gives an overview of this phase II trial, which aims to assess the efficacy of loncastuximab tesirine for the treatment of relapsed or refractory (R/R)…

Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma

Source

0
(0)

Prof Carmelo Carlo-Stella speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He gives an overview of this phase II trial, which aims to assess the efficacy of loncastuximab tesirine for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma.

Prof Carlo-Stella presents the promising initial findings from this study, which could offer a new treatment option for heavily-pretreated patients, who have failed prior therapies.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

0 / 5. 0

Leave a Reply

Your email address will not be published. Required fields are marked *